Hi-Great posts $20K sales, flags going concern
Hi-Great Group Holding Co posted a smaller net loss but continues to operate with minimal cash, a large stockholders’ deficit and a going-concern warning.
Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
10-Q
Rhea-AI Filing Summary
Hi-Great Group Holding Co (HIGR) reported that for the six months ended June 30, 2026 it generated sales of $20,210, modestly higher than $19,018 a year earlier, but remained unprofitable with a net loss of $20,167, improved from a $35,982 loss in the prior-year period.
Total assets were only $15,836 against total liabilities of $283,939, leaving a stockholders’ deficit of $268,104 and an accumulated deficit of $1,000,169. Cash was $923 at June 30, 2026, and the company disclosed substantial related-party payables, including $173,764 of accrued royalty to SellaCare, Inc. <a href="https://bitcomme.com/the-best-work-management-software-for-2026/” title=”The Best Work Management Software for 2026″>Management describes Hi-Great as a development stage enterprise focused on agritourism, SellaCare herbal supplements, and a KRAS gene licensing strategy, and states there is substantial doubt about its ability to continue as a going concern without additional financing.
Positive
- Net loss narrowed for the six months to $20,167 from $35,982 in the prior-year period, reflecting lower professional and general and administrative expenses.
- Six-month sales increased slightly to $20,210 from $19,018, while cost of sales declined, improving gross profit from $6,914 to $9,097.
Negative
- The company reports a stockholders’ deficit of $268,104 and an accumulated deficit of $1,000,169, indicating liabilities significantly exceed assets.
- Cash was only $923 at June 30, 2026 versus current liabilities of $200,689, highlighting very tight liquidity.
- There is a disclosed going-concern uncertainty because operations do not generate sufficient revenue to cover costs and the company depends on external financing.
- Accrued royalty and related-party obligations are significant, including $173,764 of licensing expense accrued to SellaCare, Inc. and $84,948 in loans payable to a related party.
- Management concluded disclosure controls and procedures were not effective as of March 31, 2025, indicating material weaknesses in internal control over financial reporting.
